[Skip to Navigation]
Sign In
Comment & Response
November 18, 2021

Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer—Reply

Author Affiliations
  • 1Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
JAMA Oncol. 2022;8(1):171-172. doi:10.1001/jamaoncol.2021.5768

In Reply We thank Dr Sorscher for his comment on our recent Original Investigation in JAMA Oncology.1 Based on our results, we had concluded that extended adjuvant bisphosphonate treatment with zoledronate for 5 years should not be considered in patients with early breast cancer in the absence of decreased bone density, and that the recommended 3 to 5 years of adjuvant bisphosphonate treatment for patients with high-risk early breast cancer as published in current clinical guidelines could be reduced.

Add or change institution